Trial Profile
CNS-reactive B cells in the blood are biomarkers for therapeutic responsiveness and disease activity in Lemtrada-treated MS patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2018
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- 13 Nov 2018 New trial record